Sanara MedTech Inc. logo

Sanara MedTech Inc.

SMTI

NASDAQHealthcareMedical - Instruments & Supplies

Previous close

$34.45

+$0.21 · +0.61%

Aug 21, 4:00 PM ET

SMTI company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

87

Deep Value

Momentum

57

Neutral

Sentiment

66

Bullish

Risk resilience

40

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
US
CEO
Seth D. Yon
Listed since
Apr 7, 1994
Employees
108

Market position

Day range

Current $34.45

52-week range

Current $34.45

Open
$34.225
Previous close
$34.24
Volume
388.92K
2.61× average
Average volume
149.21K
Average daily volume
Market cap
316.7M USD
Beta
1.16
Market reference 1
50-day average
$27.528
+25.15% above average
200-day average
$22.7524
+51.41% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
232.96M USD
EV / EBITDA
25.8×
Earnings yield
-18.66%
Free cash flow yield
1.07%

Profitability & efficiency

Return on equity
-633.46%
Return on assets
-51.50%
Return on invested capital
16.73%

Financial health

Current ratio
1.8×
Altman Z-score
3.85
Piotroski F-score
5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends103%52%2%-49%Gross margin, FY2021: 90.43%Gross margin, FY2022: 86.12%Gross margin, FY2023: 87.92%Gross margin, FY2024: 90.61%Gross margin, FY2025: 90.13%Operating margin, FY2021: -30.55%Operating margin, FY2022: -27.30%Operating margin, FY2023: -6.49%Operating margin, FY2024: -7.75%Operating margin, FY2025: 8.87%Net margin, FY2021: -32.81%Net margin, FY2022: -17.31%Net margin, FY2023: -6.62%Net margin, FY2024: -11.15%Net margin, FY2025: -36.43%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 90.43%. Gross margin FY2022 86.12%. Gross margin FY2023 87.92%. Gross margin FY2024 90.61%. Gross margin FY2025 90.13%. Operating margin FY2021 -30.55%. Operating margin FY2022 -27.30%. Operating margin FY2023 -6.49%. Operating margin FY2024 -7.75%. Operating margin FY2025 8.87%. Net margin FY2021 -32.81%. Net margin FY2022 -17.31%. Net margin FY2023 -6.62%. Net margin FY2024 -11.15%. Net margin FY2025 -36.43%.

Income trends

Revenue

103.12M USD+18.97%

Operating income

9.15M USD+15.86M USD

Net income

−37.56M USD-288.66%
Income trends across reported periods117.19M USD60.91M USD4.64M USD−51.63M USDRevenue, FY2021: 24.14M USDRevenue, FY2022: 45.84M USDRevenue, FY2023: 64.99M USDRevenue, FY2024: 86.67M USDRevenue, FY2025: 103.12M USDOperating income, FY2021: −7.38M USDOperating income, FY2022: −12.52M USDOperating income, FY2023: −4.22M USDOperating income, FY2024: −6.72M USDOperating income, FY2025: 9.15M USDNet income, FY2021: −7.92M USDNet income, FY2022: −7.94M USDNet income, FY2023: −4.3M USDNet income, FY2024: −9.66M USDNet income, FY2025: −37.56M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 24.14M USD. Revenue FY2022 45.84M USD. Revenue FY2023 64.99M USD. Revenue FY2024 86.67M USD. Revenue FY2025 103.12M USD. Operating income FY2021 −7.38M USD. Operating income FY2022 −12.52M USD. Operating income FY2023 −4.22M USD. Operating income FY2024 −6.72M USD. Operating income FY2025 9.15M USD. Net income FY2021 −7.92M USD. Net income FY2022 −7.94M USD. Net income FY2023 −4.3M USD. Net income FY2024 −9.66M USD. Net income FY2025 −37.56M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue103.12M USD86.67M USD64.99M USD45.84M USD24.14M USD
Cost of goods sold10.18M USD8.14M USD7.85M USD6.36M USD2.31M USD
Gross profit92.94M USD78.53M USD57.14M USD39.48M USD21.83M USD
Research and development5.07M USD5.7M USD4.13M USD3.37M USD558.7K USD
Selling, general, and administrative78.72M USD76.56M USD56.99M USD45.98M USD28.05M USD
Operating expenses83.79M USD85.25M USD61.35M USD52M USD29.21M USD
Interest income3.67K USD21.98K USD284.75K USD
Interest expense6.76M USD3.13M USD475.78K USD284.75K USD711 USD
Depreciation and amortization2.66M USD4.92M USD3.68M USD2.37M USD771.93K USD
Operating income9.15M USD−6.72M USD−4.22M USD−12.52M USD−7.38M USD
Net income−37.56M USD−9.66M USD−4.3M USD−7.94M USD−7.92M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-4.36
FY2025
Latest fiscal-year revenue
103.12M USD
FY2025 · +18.97% year over year
Next fiscal-year revenue consensus
116.97M USD
FY2026 · 2 analysts

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend-0.14-1.67-3.21-4.74FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend143.64M100.19M56.73M13.28MFY21FY22FY23FY24FY25FY26FY27

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$35.00

1.60% upside
Past 12 months12-month forecastHigh $35.00Average $35.00Low $35.00

Rating distribution

3 ratings

Limited analyst sample: 3 ratings. Interpret the distribution with caution.

Strong buy00%
Buy267%
Hold133%
Sell00%
Strong sell00%

Corporate actions

Corporate action history

DividendUpcoming

Ex-dividend Jul 29, 2027

$33.00

Irregular

SMTI peers

ETFs holding SMTI

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research SMTI

research.disclaimer